Clinuvel Pharmaceuticals Ltd (ASX: CUV) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Clinuvel Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $648.79 million
P/E Ratio 18.68
Dividend Yield 0.38%
Shares Outstanding 50.06 million
Earnings per share 0.698
Dividend per share 0.05
Year To Date Return -18.19%
Earnings Yield 5.35%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Clinuvel Pharmaceuticals Ltd (ASX: CUV)
    Latest News

    A man sits thoughtfully on the couch with a laptop on his lap.
    Broker Notes

    8 ASX All Ords shares bumped up to 'strong buy' status in August

    These ASX companies attracted upgraded ratings from the brokers last month.

    Read more »

    Doctor doing a telemedicine using laptop at a medical clinic
    Earnings Results

    Guess which ASX All Ords healthcare share just rocketed 13% on its FY 2024 results!

    Investors are sending the ASX All Ords healthcare share flying higher on Thursday. But why?

    Read more »

    Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
    Share Gainers

    Why Bega Cheese, Clinuvel, Dusk, and Omni Bridgeway shares are rocketing today

    These shares are standing out with strong gains on Thursday. But why?

    Read more »

    Smiling man sits in front of a graph on computer while using his mobile phone.
    Broker Notes

    Broker says buy the dip on these 4 ASX shares

    Top broker Morgans has add ratings on four ASX shares that have dipped significantly over the past month.

    Read more »

    A worried man holds his head and look at his computer.
    Share Fallers

    Why Clinuvel, Mesoblast, Red Hill, and Resimac shares are sinking today

    These shares are having a tough time on Tuesday. But why?

    Read more »

    a woman holds her hands to her temples as she sits in front of a computer screen with a concerned look on her face.
    Share Fallers

    Why Bowen Coking Coal, Clinuvel, Meteoric Resources, and Pilbara Minerals shares are falling

    These shares are starting the week in the red. But why?

    Read more »

    A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
    Share Gainers

    Why Clinuvel, Guzman y Gomez, Magellan, and Sandfire shares are charging higher

    These shares are ending the week with a bang. But why?

    Read more »

    Shot of a young scientist using a digital tablet while working in a lab.
    Healthcare Shares

    Why is this ASX 300 healthcare stock surging 12% today?

    An announcement is getting investors excited today. Let's find out what's happening.

    Read more »

    A young man talks tech on his phone while looking at a laptop. A financial graph is superimposed across the image.
    Broker Notes

    Guess which ASX 300 share could rise over 50%

    Bell Potter sees huge upside for this buy-rated stock. Let's see why it is bullish.

    Read more »

    Smiling man with phone in wheelchair watching stocks and trends on computer
    Share Market News

    5 things to watch on the ASX 200 on Tuesday

    A better session is expected for Aussie investors today.

    Read more »

    Shot of a young scientist using a digital tablet while working in a lab.
    Healthcare Shares

    Which ASX biotech shares are pioneering the future of medicine?

    Uncover the risks and rewards of high-stakes investments in ASX biotech stocks.

    Read more »

    A young female investor sits in her home office looking at her ipad and smiling as she sees the QBE share price rising
    Broker Notes

    7 ASX All Ords shares elevated to 'strong buy' status in March

    There are blue chips and small caps on this list.

    Read more »

    Frequently Asked Questions

    Yes, Clinuvel Pharmaceuticals has historically paid one unfranked shareholder dividend a year.

    Clinuvel Pharmaceuticals generally pays its shareholder dividend in September.

    Clinuvel Pharmaceuticals does not have a dividend reinvestment plan.

    Clinuvel Pharmaceuticals Limited listed on the ASX on 13 February 2001.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    05 Sep 2024 $0.0500 100.00% Final 20 Sep 2024
    05 Sep 2023 $0.0500 100.00% Final 20 Sep 2023
    06 Sep 2022 $0.0400 100.00% Final 21 Sep 2022
    02 Sep 2021 $0.0250 0.00% Final 17 Sep 2021
    03 Sep 2020 $0.0250 0.00% Final 18 Sep 2020
    04 Sep 2019 $0.0250 0.00% Final 19 Sep 2019
    21 Sep 2018 $0.0200 0.00% Final 08 Oct 2018

    CUV ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Clinuvel Pharmaceuticals Ltd

    Clinuvel Pharmaceuticals Ltd (ASX: CUV) is an Australian-based global biopharmaceutical company developing drugs for the treatment of genetic and vascular disorders. Its principal product SCENESSE is a drug for an inherited disorder, erythropoietic protoporphyria, that causes an intolerance to light.

    Its pioneering work aims at preventing the symptoms of skin diseases related to exposure to UV radiation and at repigmentation of the skin due to depigmentation disorders. Geographically, the company derives the majority of its revenue from its US and European markets.

     

    CUV Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    04 Dec 2024 $12.96 $0.00 0.00% 153,725 $12.90 $12.96 $12.56
    03 Dec 2024 $12.96 $-0.08 -0.61% 62,453 $12.97 $13.09 $12.87
    02 Dec 2024 $13.04 $-0.11 -0.84% 78,884 $13.23 $13.44 $12.95
    29 Nov 2024 $13.15 $0.06 0.46% 61,470 $13.10 $13.20 $12.97
    28 Nov 2024 $13.09 $0.05 0.38% 82,827 $13.09 $13.34 $12.95
    27 Nov 2024 $13.04 $-0.04 -0.31% 68,534 $13.08 $13.12 $12.90
    26 Nov 2024 $13.08 $0.17 1.32% 73,811 $12.95 $13.11 $12.87
    25 Nov 2024 $12.91 $-0.13 -1.00% 143,320 $12.99 $13.10 $12.80
    22 Nov 2024 $13.04 $-0.12 -0.91% 170,135 $13.12 $13.28 $12.94
    21 Nov 2024 $13.16 $-0.24 -1.79% 128,886 $13.49 $13.79 $13.10
    20 Nov 2024 $13.40 $-0.22 -1.62% 102,706 $13.67 $13.83 $13.24
    19 Nov 2024 $13.62 $0.05 0.37% 140,614 $13.60 $14.05 $13.51
    18 Nov 2024 $13.57 $0.29 2.18% 113,225 $13.31 $13.63 $13.01
    15 Nov 2024 $13.28 $-0.25 -1.85% 86,459 $13.55 $13.62 $13.25
    14 Nov 2024 $13.53 $-0.16 -1.17% 34,759 $13.70 $13.87 $13.52
    13 Nov 2024 $13.69 $0.06 0.44% 49,180 $13.63 $13.94 $13.59
    12 Nov 2024 $13.63 $0.12 0.89% 42,765 $13.55 $13.77 $13.43
    11 Nov 2024 $13.51 $-0.19 -1.39% 36,700 $13.70 $13.70 $13.48
    08 Nov 2024 $13.70 $0.12 0.88% 54,819 $13.53 $13.76 $13.42
    07 Nov 2024 $13.58 $-0.10 -0.73% 86,040 $13.75 $13.90 $13.34
    06 Nov 2024 $13.68 $-0.05 -0.36% 94,450 $13.88 $14.03 $13.57
    05 Nov 2024 $13.73 $0.12 0.88% 61,006 $13.55 $13.90 $13.54

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mrs Susan (Sue) Smith Non-Executive Director Sep 2019
    Mrs Smith manages an established consultancy business, providing advisory services to a range of healthcare organisations, investors, and boards of directors. She has led a career, serving for 14 years as Chief Executive Officer of The Princess Grace Hospital, London, and 11 years as the Chief Executive Officer of The Portland Hospital for Women and Children, London. Mrs Smith's specific expertise is in the implementation of operational strategies within complex and acute care environments, and in the interaction with healthcare authorities and UK regulators. Her most recent role was as the Chief Executive Officer of the Independent Doctors Federation, a membership organisation representing practising physicians within the UK independent healthcare sector.
    Dr Philippe J Wolgen Chief Executive OfficerManaging Director Dec 2005
    Dr Wolgen's leadership led to a long-term strategy for CLINUVEL. The product SCENESSE was reformulated, its medical application identified, European marketing authorisation was obtained in 2014 and systems were established to self-distribute the prescriptive product in the European Economic Area from June 2016. Dr Wolgen oversaw the submission of the scientific dossier to the US Food & Drug Administration (FDA) under a New Drug Application, which was approved in October 2019.
    Dr Karen Agersborg Non-Executive Director Jan 2018
    Dr Agersborg has diverse and practice experience in Pennsylvania and New Jersey, USA. She is Board Certified in both Internal Medicine and Endocrinology, Diabetes & Metabolism and holds specific expertise on the class of melanocortins. Her career has included inpatient, outpatient, and hospitalist positions across several prominent medical institutions. Dr Agersborg had career in managing commercial sales & distribution at Wyeth Pharmaceuticals (formerly Ayerst Laboratories).
    Dr Jeffrey Rosenfeld Non-Executive ChairmanNon-Executive Director Nov 2019
    Prof Rosenfeld is a neurosurgeon with experience in senior healthcare and medical research executive roles and career in the Australian Army. He is a retired Major General and a former Surgeon General, Australian Defence Force-Reserves. He has served on eight deployments to Rwanda, Iraq, Solomon Islands, Bougainville, and East Timor. He was the Founding Director of Monash University Institute of Medical Engineering (MIME)-Melbourne. He is developing a bionic vision device to restore vision in people without eyesight, and he is also an adviser in brain injury research. He is also member of the Risk Committee.
    Mr Matthew William Pringle Non-Executive Director Sep 2024
    Mr Pringle has experience in corporate finance, audit and assurance, governance and strategy, including over 25 years experience as a Partner at Pitcher Partners. His roles with Pitcher Partners included leading the corporate finance practice group, senior audit partner and leading the corporate governance and board advisory practice area.He is a director of Navalo Financial Services Group Limited, Hypersonix Launch Systems Limited, and the not-for-profit Anglicare Victoria.
    Dr Pearl E Grimes Non-Executive Director Sep 2024
    Dr Grimes is a dermatologist and a leading international authority on vitiligo and pigmentation disorders. She is the Founder and Director of the Vitiligo and Pigmentation Institute of Southern California where she treats patients from all over the world. Dr Grimes is also the director of the Grimes Institute for Medical and Aesthetic Dermatology, where she expertly treats a range of dermatologic health and aesthetic concerns in patients of all ethnicities and skin types. Dr Grimes also serves as a Clinical Professor of Dermatology at the David Geffen School of Medicine at UCLA and Chief Dermatologist for Versicolor Technologies.
    Mr Guy van Dievoet Non-Executive Director Sep 2024
    Mr van Dievoet has experience in investment banking, specialising in M&A. In this capacity he has worked for financial institutions, including the Merchant bank of IndoSuez in Belgium, ABN-AMRO, Bank BNP Group, and as executive-director for MeesPierson. Over the years he has provided strategic support on corporate growth, structuring and buy-build approaches, and assisted companies listing on the Brussels and Amsterdam Stock Exchanges (EuroNext).
    Ms Claire Newstead-Sinclair Company Secretary Aug 2024
    -
    Darren Keamy CFO & Company Secretary
    -
    Peter Vaughan Chief Financial Officer
    -
    Lachlan Hay Chief Operations Officer
    -
    Dennis Wright Chief Scientific Officer
    -
    Claire Newstead-Sinclair Company Secretary
    -
    Linda Teng Director of North American Operations
    -
    Emilie Rodenburger Director Global Clinical Affairs
    -
    Malcolm Bull Head of Australian Operations and Investor Relations
    -
    Azza Hamila Head of Quality Assurance and Drug Safety
    -
    Rose Quadbeck-Diel Snr VP Regulatory Affairs
    -
    Antonella Colucci VP Commercial Affairs
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Ltd 10,225,972 20.42%
    BNP Paribas Nominees Pty Ltd ACF (Clearstream) 5,685,193 11.35%
    BNP Paribas Nominees Pty Ltd 4,988,645 9.96%
    J P Morgan Nominees Australia Pty Limited 3,629,550 7.25%
    Dr Philippe Jacques Wolgen 3,425,222 6.84%
    Citicorp Nominees Pty Limited 3,416,310 6.82%
    Ender 1 LLC 2,590,824 5.17%
    BNP Paribas Nominees Pty Ltd (IB AU Noms Retail Client) 2,207,904 4.41%
    HSBC Custody Nominees (Australia) Ltd A/C2 922,480 1.84%
    Emilino Group Pty Ltd (Emilino Super Fund) 601,447 1.20%
    National Nominees Limited 548,778 1.10%
    Mr Darren Michael Keamy 362,890 0.72%
    Dr Mark Edwin Badcock 346,772 0.69%
    Mr David William Trevorrow 229,600 0.46%
    BNP Paribas Nominees Pty Ltd (Agency Lending A/C) 229,044 0.46%
    Dr Dennis Wright 188,812 0.38%
    Mr David John Lewis 185,000 0.38%
    Mr Trent Sheldon Redding 177,370 0.35%
    Rusty Hammer Pty Ltd (Archipelago Holdings SF A/C) 150,722 0.30%
    Mr Simon John Bown 146,000 0.29%

    Profile

    since

    Note